Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.

Abstract

AIM:

Ipragliflozin is a new antidiabetic agent that works through enhancing renal glucose excretion. We aim to synthesize evidence from published randomized controlled trials (RCTs) on the safety and efficacy of ipragliflozin in the management of type 2 diabetes mellitus (T2DM).

METHODS:

We searched PubMed, Scopus, Web of Science, and Cochrane Central register of clinical trials using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup and sensitivity analyses were conducted.

RESULTS:

We included 13 RCTs (N=2535 patients) in the final analysis. The overall effect estimates favoured ipragliflozin 50mg monotherapy group over placebo in terms of: HbA1c (Standardized mean difference (SMD)=-1.20%, 95% Confidence interval (95% CI)=[-1.47, -0.93]; p<0.001), fasting plasma glucose (SMD=-1.30 mg/dL, 95% CI [-1.93, -0.67]; p<0.001), fasting serum insulin (SMD=-1.64 μU/mL, 95% CI [-2.70, -0.59]; p=0.002), and body weight (SMD=-0.85 kg, 95% CI [-1.19, -0.51]; p<0.001). Similarly, better glycemic control and significant body weight reduction compared to placebo were attained in ipragliflozin 50 mg combination with metformin, insulin with/without dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone. Ipragliflozin, either alone or in combination, exhibits acceptable safety profile.

CONCLUSION:

The presented meta-analysis provides class one evidence that ipragliflozin is safe and effective in the management of T2DM either as monotherapy or an add-on.

• Authors: Ahmed Elgebaly, Nesrine Abdelazeim, Bassant Abdelazeim, Gehad El Ashal, Omar Mattar, Lubaba Namous, Noha Nasreldin
• Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (Exp Clin Endocrinol Diabetes) Vol. 129 Issue 1 Pg. 56-72 (Jan 2021) ISSN: 1439-3646 [Electronic] Germany
• PMID: 29913526 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: Thieme. All rights reserved.

Chemical References

• Glucosides
• Sodium-Glucose Transporter 2 Inhibitors
• Thiophenes
• ipragliflozin

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Glucosides (administration & dosage, adverse effects, pharmacology)
• Humans
• Outcome Assessment, Health Care (statistics & numerical data)
• Sodium-Glucose Transporter 2 Inhibitors (administration & dosage, adverse effects, pharmacology)
• Thiophenes (administration & dosage, adverse effects, pharmacology)